Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

8.75
+0.22002.58%
Post-market: 8.74-0.0100-0.11%18:37 EST
Volume:916.91K
Turnover:7.81M
Market Cap:442.95M
PE:-2.53
High:8.76
Open:8.55
Low:8.24
Close:8.53
52wk High:16.19
52wk Low:5.04
Shares:50.62M
Float Shares:41.42M
Volume Ratio:1.21
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4644
EPS(LYR):-4.5871
ROE:-76.88%
ROA:-18.54%
PB:2.74
PE(LYR):-1.91

Loading ...

Rosen Law Firm Urges Regenxbio Investors to Act Ahead of April 14 Lead Plaintiff Deadline

Reuters
·
Yesterday

Regenxbio Inc. to Host Conference Call on Quarterly and Full-Year Financial Results

Reuters
·
Feb 25

Pomerantz Law Firm Files Class Action Lawsuit Against Regenxbio Inc

Reuters
·
Feb 25

Regenxbio Faces Securities Class Action Lawsuit

Reuters
·
Feb 24

Faruqi & Faruqi Alerts Regenxbio Investors to April 14, 2026 Securities Class Action Deadline

Reuters
·
Feb 21

US court revives Regenxbio patent lawsuit over muscular dystrophy treatment

Reuters
·
Feb 21

Regenxbio Wins Appeal in Patent Dispute With Sarepta Therapeutics

MT Newswires Live
·
Feb 21

Court revives Regenxbio, UPenn patent suit against Sarepta, Bloomberg says

TIPRANKS
·
Feb 21

Rosen Law Firm Files Securities Class Action Against Regenxbio Inc

Reuters
·
Feb 20

Class Action Lawsuit Targets REGENXBIO Inc

Reuters
·
Feb 19

Investors File Class Action Lawsuit Against Regenxbio Inc

Reuters
·
Feb 18

Regenxbio Faces Class Action Lawsuit Over RGX-111 Trial Disclosures

Reuters
·
Feb 16

Regenxbio Faces Class Action Lawsuit After FDA Halts Gene Therapy Trial

Reuters
·
Feb 14

Regenxbio Inc - Entered Into Sales Agreement With Leerink Partners for Common Stock - SEC Filing

THOMSON REUTERS
·
Feb 13

FDA Rejects Regenxbio's Gene Therapy for Hunter Syndrome

Deep News
·
Feb 11

BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog​, Ecolab

Reuters
·
Feb 10

REGENXBIO Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Feb 10

Regenxbio price target lowered to $32 from $34 at H.C. Wainwright

TIPRANKS
·
Feb 10

Regenxbio Inc. : H.c. Wainwright Cuts Target Price to $32 From $34

THOMSON REUTERS
·
Feb 10

REGENXBIO Is Maintained at Buy by Chardan Capital

Dow Jones
·
Feb 10